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Abstract
We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed
leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with
intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT) trastuzumab was introduced to
enhance HER-2+ therapy into the CSF space. A combination HER-2+ targeted approach achieved clinical remission
with stable disease in our patient 46 months after she was diagnosed with LM metastases. However, spinal cord
C-1 metastasis was not fully controlled with IT trastuzumab, ultimately leading to the patient’s respiratory
compromise. In our patient, IT trastuzumab immunotherapy improved prognosis and was an effective strategy to
manage HER-2+ LM disease. Given alone or alongside other anti-HER-2+ therapeutics with sufficient CNS
penetration, IT trastuzumab could extend the lifespan of patients with leptomeningeal and CNS metastases.
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Background
Trastuzumab (Herceptin; Roche, Basel, Switzerland) is a
humanized monoclonal IgG1 antibody which has revolu-
tionized the outcome of patients with HER-2 overexpress-
ing breast cancer. Traditionally, HER-2 overexpressing
tumors have been associated with more aggressive disease
and inferior prognosis, resulting in shorter survival [1, 2].
However, trastuzumab has transformed HER-2+ breast
cancer into one of the most treatable types of cancer. The
efficacy of trastuzumab partially relies on its immunologic
ability to recruit natural killer lymphocytes to HER-2+
tumors via the antibody dependent cellular cytotoxicity
(ADCC) mechanism [3].
Trastuzumab’s control of systemic disease in HER-2+
breast cancer patients has led to a higher incidence of
CNS metastases [4]. HER-2+ metastases can develop in
areas where intravenous (IV) trastuzumab has little to
no penetration, particularly the central nervous system
(CNS) where brain and leptomeningeal (LM) metastases
can occur. The development of this complication war-
rants a multi-faceted approach. Extramedullary lepto-
meningeal metastases require drug penetration through
the blood–brain barrier or blood CSF barrier. Intrame-
dullary metastases (brain and spinal cord) bury deeper
in the neural tissue and are therefore more difficult
lesions to treat. As trastuzumab is highly effective against
systemic HER-2+ breast cancer, a logical strategy is to
investigate its ability to target HER-2+ CNS metastases.
As a single-agent first line therapy for HER-2+ breast
cancer, trastuzumab achieved a response rate of 25–35 %
[5]. Among women with metastatic breast cancer who
progressed after standard chemotherapy, trastuzumab
yielded response rates of 15–18 % [6] as a second and
third line therapy. Several adjuvant (NSABP B-31, BCIRG
006, NCCTG N9831, HERA) [7–9] and neoadjuvant
(NOAH, Neo-ALTTO) [10, 11] trials have demonstrated
that combining trastuzumab with standard chemotherapy
reduces the risk of recurrence and mortality compared to
chemotherapy alone in these patients.
Trastuzumab benefits women at any stage of HER-2+
breast cancer and is currently part of the standard of
care. Given its demonstrated safety and efficacy, using
trastuzumab to target HER-2+ tumor cells that have
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spread to the cerebrospinal fluid (CSF) by intrathecal
administration is a plausible strategic intervention for
impacting the prognosis for patients with LM metastases.
Yet, intrathecal (IT) trastuzumab has not been formally
tested in a prospective fashion. Despite accumulating
anecdotal reports suggesting tolerability and good antitu-
mor activity for leptomeningeal metastases [12–16], IT
trastuzumab is underutilized as a treatment modality for
HER-2+ LM from breast cancer. Our challenge remains:
To implement an effective dose schedule of IT trastuzu-
mab in combination with other standard therapies to
manage both the extramedullary and intramedullary HER-
2+ CNS lesions.
We report a case of a patient who developed LM
disease after achieving clinical remission of her meta-
static HER-2+ systemic disease with IV trastuzumab.
By initiating IT trastuzumab in combination with
modalities that can deliver anti-HER-2 therapy across
the blood–brain barrier, we halted the progression of
HER-2 invasion in the CSF and achieved the longest
control of LM disease ever reported to date
(>46 months).
Case Presentation
The patient’s timeline of disease progression and treat-
ment is outlined in Table 1. In April 2003, a 41-year-old
woman was diagnosed with stage II breast cancer
(T1N1M0, ER/PR-, HER-2/ 3+ by immunohistochemis-
try). She was treated with surgery and adjuvant chemo-
therapy (Adriamycin/Cytoxan, and weekly docetaxel). In
March 2007, she developed liver, lungs, lymph nodes,
and skeletal metastases. She received gemcitabine plus
docetaxel, concurrent with IV trastuzumab and zoledro-
nic acid. Subsequent scans showed significant response
with clinical remission.
Three years later, the patient presented with loss of hear-
ing in her left ear and a left facial droop. This led to the
diagnosis of recurrence in the left internal auditory canal
(IAC) and LM. CSF analysis showed no tumor cells.
Cyberknife therapy for IAC tumors as well as treatment
with lapatinib (Tykerb; Glaxo-SmithKline, Philadelphia,
PA) + capecitabine (Xeloda; Roche, Basel, Switzerland)
resulted in significant improvement in neurological symp-
toms and imaging studies. She declined whole brain radi-
ation and IT methotrexate. She gave informed consent,
Table 1 Treatment Timeline
Date Disease Progression Treatment Serum CA 27.29
(U/mL)
April-2003 Diagnosed with stage II breast cancer Surgery and adjuvant chemotherapy (adriamysin/cytoxan,
and weekly docataxel)
na
March-2007 Developed liver, lungs, lymph nodes,
and skeletal metastases
Chemotherapy (gemcitabine/docetaxel with concurrent
IV trastuzumab/zoledronic acid), resulted in clinical remission
na
April-2010 Loss of hearing and left facial with
recurrence in left internal auditory
canal and LM
Cyberknife therapy for IAC tumors and chemotherapy
(lapatinib/capecitabine), resulted in significant improvement
in neurological symptoms and imaging
na
October-2010 Ommaya inserted Experimental IT trastuzumab (5 mg flat dose per week) 12.3
January-2011 New parenchymal, thoracic and
lumbar LM metastases with additional
5th cerebral nerve and c1 lesions
Whole brain and spine radiation and increased IT trastuzumab
(10 mg per week)
12.6
July-2011 Worsening intramedullary c1 lesions One month of IT trastuzumab (50–80 mg per week) and
maximal dose of cyber knife therapy
32.8
March-2013 Developed weakness in left hip/leg
and enhancement in previously stable
thoracic and lumbar lesions
Increased total dose of IT trastuzumab (50–80 mg BIW, dose
divided twice per week) administered by lumbar puncture
and ommaya reservoir injections
40
May-2013 No discernable change in disease
progression
Trastuzumab (administered bimonthly for maintenance at
50 % of the weekly dose) and lapatinib (750 mg, BID five
days weekly), resulted in decreased enhancement and activity
of thoracic and lumbar lesions
59
June-2013 Diagnosed with meningitis Extended antibiotic treatment for two plus months (vancomycin) 58
July-2013 Hiatus from IT with an increase in
CA27.29
T-DM1 37
August-2013 Removed ommaya 50
September-2013 New ommaya inserted Restarted IT trastuzumab (40 mg per week) 50
October-2013 Worsening neurological symptoms IT trastuzumab 50 mg (100 mg per week) 40
August-2014 Patient expired 40
Na not available (patient at different clinic)
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however, to have an ommaya reservoir placed to begin ex-
perimental IT trastuzumab. This study was in accordance
with the World Medical Association (WMA) Declaration
of Helsinki. Ethical approval was waived by the University
of California Los Angeles Office of the Human Research
Protection Program (UCLA-OHRPP).
Given the wide range of IT trastuzumab dosages re-
ported in the literature (flat dosing, ranging from 5
to 100 mg weekly), we started with the lowest dose
of 5 mg weekly to assess safety and any efficacy.
Three months later, new brain parenchymal, thoracic
and lumbar spinal LM metastases, plus 5th cerebral
nerve and C1 lesions prompted treatment with cra-
niospinal radiation, followed by a higher dose of IT
trastuzumab. We first increased the dose to 10 mg,
and then later to 25 mg, given every 2 weeks. These
measures stabilized known CNS lesions. Six months
later, however, a worsening intramedullary C1 lesion
suggested that the IT trastuzumab dosage might be
inadequate to treat lesions inside of the spinal cord.
To treat worsening lesions, IT trastuzumab was in-
creased to 50–80 mg administered once per week for
a month. The patient’s C1 lesion also underwent a
maximal dose of cyberknife therapy.
The weekly dose escalation of IT trastuzumab resulted
in stable disease until March 2013, when the patient
developed weakness in her left hip and leg. Magnetic
resonance imaging (MRI) revealed enhancement in the
previously stable thoracic and lumbar LM lesions. The
patient was given an increased total dose of IT trastuzu-
mab, administered twice weekly by lumbar puncture and
ommaya reservoir injections (50–80 mg divided twice
per week × one month). After one month, the dose was
tapered down and administered every 2 weeks, for main-
tenance at 50 % of the weekly dose. To further target
intramedullary lesion, we implemented a pulsing oral
lapatinib regimen (750 mg) twice a day (BID) for five
days out of seven days until clinical or radiological
evidence of tumor progression [17]. These treatments
resulted in decreased enhancement and activity of the
thoracic and lumbar lesions on the spinal cord.
The increase in dosing and frequency of IT trastuzu-
mab was generally well tolerated, except for an episode
of meningitis in June 2013, which required removal of
the ommaya reservoir and over 2 months of antibiotic
treatment. After completion of antibiotics, a new
ommaya reservoir was inserted. Without IT trastuzu-
mab, a significant increase in the serum CA27.29 tumor
marker was successfully normalized with a short course
of T-DM1 administered in July 2013 treatment.
Three and a half years after having started IT trastuzu-
mab, our patient experienced further decline in her left
sided motor function and was wheelchair bound. The
decreasing functional capacity of the left side likely cor-
related with the worsening C1 intramedullary lesion seen
on MRI (Fig. 1). We attempted, once again, a higher
dose and frequency of IT trastuzumab, as well as re-
evaluating for potentially re-treatable cyberknife lesions
without success. Despite physical decline, the patient’s
performance status remained sufficient enough to allow
her continued parenting of two adolescent children.
Eleven years after her HER-2+ breast cancer was diag-
nosed, she expired from respiratory compromise due to
progressive C1 intramedullary lesion.
Discussion
Pervasive HER-2+ breast cancer cells can travel long dis-
tances and break virtually any protective barrier in the
body. To combat HER-2+ CNS metastases and improve
patient survival, one must have the means to deliver
effective anti-HER-2 immunotherapy to any site of dis-
ease. In order to improve prognosis, there is a need for a
multi-modality approach against HER-2+ cells in the
CSF that create LM, brain, and spinal cord lesions.
Fig. 1 Intramedullary lesion at C1-C2 with associated cord edema
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IT trastuzumab was effective in targeting extramedul-
lary (LM) metastases. This resulted in the prolonged sur-
vival of our patient for 46 months, compared to a
median life expectancy of 3–4 months for breast cancer
patients following the diagnosis of LM without treat-
ment [18]. Given that IV trastuzumab does not cross the
blood–brain barrier or blood CSF barrier, IT trastuzu-
mab offers a direct approach to the leptomeninges. IT
trastuzumab immunotherapy delivers an optimal drug
concentration to the CSF and is surprisingly well toler-
ated compared to chemotherapy, such as IT methotrex-
ate. IT methotrexate can be associated with severe side
effects including meningoencephalopathy, leukoencepha-
lopathy, stomatitis, and marrow suppression [19].
Furthermore, dose escalation of IT trastuzumab enabled
disease management in our patient. When imaging re-
vealed a worsening of old lesions, the appearance of new
spots, or when new neurological symptoms emerged, in-
creasing the dose of trastuzumab achieved subsequent
stable scans and slowed the patient’s functional decline.
High-dose IT trastuzumab, however, must be adminis-
tered with great caution. In our experience, CSF proteins
that may cause cerebral edema and/or intracranial hyper-
tension can increase with doses higher than 50 mg weekly
(Table 2). To prevent this, we have administered up to
80 mg IT trastuzumab weekly in divided doses (40 mg bi-
weekly × 4 weeks) (Table 3). These higher doses were given
concurrently via lumbar puncture and ommaya reservoir
to ensure more uniform drug distribution in the CSF.
If new CNS lesions were to appear in the lower spinal
cord, a CSF flow study might help to assess ommaya ad-
ministered drug dristribution. If there is poor flow, we
hypothesize that lumbar puncture administration in
addition to ommaya injection would allow trastuzumab
to reach the lumbar and thoracic LM areas more easily.
This could rapidly stabilize lower spinal cord LM lesions
and minimize further neurological deterioration.
In our experience, imaging and neurological symptoms
have been more sensitive than cytology in monitoring
LM/CNS progression. Although one other study has
documented that serial CSF cytology has 90 % sensitivity
in diagnosing LM/CNS progression [20], we have never
had a positive cytology in this case. Despite cytology’s
low sensitivity in our patient, we noted her elevated
serum CA27.29 correlated with worsening neurological
symptoms. Thus, the serum CA27.29 tumor marker has
provided an additional way to follow our patient’s LM/
CNS progression.
Although IT trastuzumab treatment of extramedullary
metastases has greatly extended the patient’s lifespan,
intramedullary metastases remain a problem and are re-
sponsible for her functional decline and eventual death.
In order to address this problem, more effective methods
will have to be developed to target intramedullary me-
tastases. Currently, treatments for intramedullary lesions
include radiation, stereotactic radiosurgery, chemother-
apy, microsurgery, and steroids [18]. These non-
immunotherapeutic options can be associated with high
neurotoxicity and disease recurrence. Each of these op-
tions has limitations. Surgery may not always be an op-
tion due to tumor location or disease burden. Tissue
tolerance may prevent multiple treatments with radi-
ation as it can cause radiation necrosis. Chemotherapy
can have systemic and neuro-toxicity and may not pene-
trate into the CNS. In addition, the standard non-
immunotherapeutic option using IT methotrexate only
has a median overall survival of approximately 2–7
months in those with breast cancer following the diag-
nosis of LM with standard IT chemotherapy [21]. In
contrast, IT trastuzumab immunotherapy could improve
the prognosis of HER-2+ LM disease, as demonstrated
by our patient’s 46 month survival.
A comprehensive, targeted approach against HER-2+
CNS disease is in sight. A phase I/II dose escalation of
IT trastuzumab (Intrathecal Trastuzumab for Leptomen-
ingeal Metastases in HER2+ Breast Cancer; Clinical-
Trials.gov number, NCT01325207) by Dr. Jeffrey Raizer,
is underway. This trial is now in phase II and unpub-
lished data presented by Dr. Jeffrey Raizer's team sug-
gests that there is more activity at the highest doses
used (Phase I trial of intrathecal trastuzumab in HER2
positive leptomeningeal metastases, 19th Annual Scien-
tific Meeting and Education Day of the Society for
Neuro-Oncology). Based on our experience, we predict
that the high efficiency of trastuzumab makes it a prom-
ising candidate to favorably impact the prognosis of pa-
tients with LM metastases from HER-2+ breast cancer.
While its activity on extramedullary lesions is apparent,
IT trastuzumab alone isn’t adequate to prevent brain or
intramedullary metastases. Lapatinib, a tyrosine-kinase
Table 2 CSF Analysis on Weekly 50 mg IT Trastuzumab
Week 1 2 3 4
Protein (g/L) 31 52a 50a 68a
RBC (/cmm3) 519 74 15 <1
WBC (/cmm3) <1 3 2 <1
Table 3 CSF Analysis on Biweekly 40 mg IT Trastuzumab (Total
80 mg Weekly)
Week 1 2 3 4
Protein (g/L) 34 28 33 26 30 31 61a
RBC (/cmm3) <1 1 <1 1 <1 1 1
WBC (/cmm3) <1 <1 <1 1 2 1 <1
CSF samples were obtained prior to IT Trastuzumab injection
IT intrathecal, CSF cerebrospinal fluid, RBC red blood cell, WBC white blood cell
aindicates high CSF protein
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inhibitor that targets HER-2, together with capecitabine,
provide a sound, concomitant treatment that has displayed
clinical activity against brain metastases from HER-2 over-
expressing breast cancer [23]. Stereotactic radiosurgery
can control CNS parenchymal disease progression, if its
dose has not been maximally implemented. Moreover,
trastuzumab could be combined with other antibody
based therapies like pertuzumab (Perjeta; Roche, Basel,
Switzerland) to improve response rates mirroring the syn-
ergistic mechanisms of new treatments for systemic meta-
static HER-2+ disease [24]. However, dual antibody
treatment requires consideration when treating the CNS
as there can be an issue with higher protein in the CSF.
Other immunotherapeutic advances to improve HER-2
+ disease prognosis are also currently in development.
Trials now focus on the discovery of tumor-associated
antigens (i.e., E75-specific CD8 + T cells that lysed HER-
2/neu expressing tumor cells) to create vaccines that fur-
ther stimulate the patient’s own immune system [25].
Peptide-based vaccines use these antigenic epitopes to
induce immune regulators, including: antibodies, helper
T-cells, and cytotoxic T-lymphocytes. The immune regu-
lators, then, recognize and lyse tumor cells expressing
the surface immunogenic peptide [26]. The concept of
using immune cells to carry out anti-tumor activities is
also apparent in how T-cell immunotherapy can mediate
durable regressions of several refractory solid tumors
[27, 28]. Similarly, checkpoint inhibitors are immune-
oncologic agents with promising activity on melanoma
brain metastases [29]. Preliminary findings suggest that
this class of compounds may have an extended role
against other CNS metastases. More clinical studies will
be needed to improve these new immunotherapeutic
interventions when targeting CNS disease in the future.
Conclusion
This is an exciting era of using immunotherapy for
HER-2+ cancers. In particular, trastuzumab (Herceptin)
has paved the way for HER-2+ breast cancer patients to
fight their disease. Due to the incidence of CNS involve-
ment in these patients, there is a great need for an
effective approach to target HER-2+ lesions in the lepto-
meninges and parenchyma of the spinal cord and brain.
A number of case studies provide favorable evidence to
support the conclusion that IT trastuzumab extends the
lives of women with HER-2+ LM metastases. We
recognize its role in improving patient prognosis and
supporting innovative IT immunotherapy as a crucial
component for the management of HER-2+ LM disease.
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